Retreatment With Sofosbuvir Plus Grazoprevir/Elbasvir Plus Ribavirin of Patients With Hepatitis C Virus Genotype 1 or 4 Who Previously Failed an NS5A- or NS3-Containing Regimen: The ANRS HC34 REVENGE Study

Abstract : Background: Failure to achieve sustained virological response (SVR) with hepatitis C virus (HCV) direct-acting antiviral (DAA)–based regimens is commonly associated with emergence of resistance-associated substitutions (RASs). Retreatment of patients who failed prior DAAs remains challenging. The aim of this prospective and randomized study was to evaluate the efficacy (primary endpoint: SVR 12 weeks after end of treatment [SVR12]) and safety of sofosbuvir + grazoprevir/elbasvir + ribavirin for 16 or 24 weeks in patients who had failed to achieve SVR on previous NS5A- or NS3-based therapy and with evidence of RASs at failure. Methods: Patients were chronically infected with HCV genotype 1 or 4. Most of them had advanced fibrosis or compensated cirrhosis (liver stiffness 5.8–48.8 kPa). Results: All patients achieved HCV RNA below the lower limit of quantification (either target detected [unquantifiable] or target not detected) during treatment. SVR12 was achieved by 25 of 26 patients. The only patient who did not reach SVR was a patient who died, but HCV RNA was negative at this time (5 weeks after stopping treatment). No patient discontinued treatment because of adverse events or virological failure. Globally, treatment was well tolerated. Conclusions: Our findings support the concept of retreating with sofosbuvir + grazoprevir/elbasvir + ribavirin, for 16 weeks, genotype 1 or 4 DAA-experienced patients with proven NS5A or NS3 RASs.
Complete list of metadatas

Cited literature [9 references]  Display  Hide  Download

https://hal-univ-rennes1.archives-ouvertes.fr/hal-01743768
Contributor : Laurent Jonchère <>
Submitted on : Friday, April 13, 2018 - 11:16:53 AM
Last modification on : Thursday, February 20, 2020 - 6:16:02 PM

File

Retreatment with sofosbuvir pl...
Files produced by the author(s)

Identifiers

Citation

Victor de Ledinghen, Claire Laforest, Christophe Hezode, Stanislas Pol, Alain Renault, et al.. Retreatment With Sofosbuvir Plus Grazoprevir/Elbasvir Plus Ribavirin of Patients With Hepatitis C Virus Genotype 1 or 4 Who Previously Failed an NS5A- or NS3-Containing Regimen: The ANRS HC34 REVENGE Study. Infectious Diseases in Clinical Practice, Lippincott, Williams & Wilkins, 2018, 66 (7), pp.1013-1018. ⟨10.1093/cid/cix916⟩. ⟨hal-01743768⟩

Share

Metrics

Record views

552

Files downloads

268